Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1997 Dec;151(6):1759–1765.

Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: cell kinetic features of neuroendocrine cells in the human prostate.

Y Xue 1, A Verhofstad 1, W Lange 1, F Smedts 1, F Debruyne 1, J de la Rosette 1, J Schalken 1
PMCID: PMC1858366  PMID: 9403726

Abstract

We investigated the keratin phenotype and bcl-2 immunoreactivity of neuroendocrine cells in the human prostate to determine whether the postmitotic status of these cells is associated with protection from apoptosis by bcl-2 protein expression and to elucidate the possible cell kinetic relationship between neuroendocrine cells and the other epithelial components of the prostate. Tissue specimens were selected from prostates of 19 patients harboring normal secretory glands (n = 15) and glandular benign prostatic hyperplasia (n = 10). Using a novel sequentially selective destaining immunoenzymatic cytochemical technique we were able to demonstrate the distribution of neuroendocrine cells, keratin markers identifying either basal, luminal, or intermediate cells, and the bcl-2 protein in single sections. Basal cell keratins were expressed in the minority of the neuroendocrine cells. In most of the cells, intermediate and luminal cell keratins were found and bcl-2 was constantly negative. Our findings indicate that neuroendocrine cells and other epithelial cells in the human prostate share a common keratin phenotype and probably originate from a common epithelial precursor. From the absence of bcl-2 we infer that the neuroendocrine cells have no progenitor cell characteristics.

Full text

PDF
1759

Images in this article

1763Figure 2
on p.1763

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aprikian A. G., Cordon-Cardo C., Fair W. R., Reuter V. E. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer. 1993 Jun 15;71(12):3952–3965. doi: 10.1002/1097-0142(19930615)71:12<3952::aid-cncr2820711226>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  2. Boise L. H., González-García M., Postema C. E., Ding L., Lindsten T., Turka L. A., Mao X., Nuñez G., Thompson C. B. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993 Aug 27;74(4):597–608. doi: 10.1016/0092-8674(93)90508-n. [DOI] [PubMed] [Google Scholar]
  3. Bonkhoff H., Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate. 1996 Feb;28(2):98–106. doi: 10.1002/(SICI)1097-0045(199602)28:2<98::AID-PROS4>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  4. Bonkhoff H., Stein U., Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol. 1993;423(4):291–294. doi: 10.1007/BF01606893. [DOI] [PubMed] [Google Scholar]
  5. Bonkhoff H., Stein U., Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol. 1995 Feb;26(2):167–170. doi: 10.1016/0046-8177(95)90033-0. [DOI] [PubMed] [Google Scholar]
  6. Bonkhoff H., Stein U., Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol. 1994 Jan;25(1):42–46. doi: 10.1016/0046-8177(94)90169-4. [DOI] [PubMed] [Google Scholar]
  7. Bubendorf L., Sauter G., Moch H., Schmid H. P., Gasser T. C., Jordan P., Mihatsch M. J. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol. 1996 Apr;178(4):437–441. doi: 10.1002/(SICI)1096-9896(199604)178:4<437::AID-PATH484>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  8. Cockett A. T., di Sant'Agnese P. A., Gopinath P., Schoen S. R., Abrahamsson P. A. Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Urology. 1993 Nov;42(5):512–519. doi: 10.1016/0090-4295(93)90260-h. [DOI] [PubMed] [Google Scholar]
  9. Cohen R. J., Glezerson G., Taylor L. F., Grundle H. A., Naudé J. H. The neuroendocrine cell population of the human prostate gland. J Urol. 1993 Aug;150(2 Pt 1):365–368. doi: 10.1016/s0022-5347(17)35484-8. [DOI] [PubMed] [Google Scholar]
  10. Colombel M., Symmans F., Gil S., O'Toole K. M., Chopin D., Benson M., Olsson C. A., Korsmeyer S., Buttyan R. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993 Aug;143(2):390–400. [PMC free article] [PubMed] [Google Scholar]
  11. Coppola D., Clarke M., Landreneau R., Weyant R. J., Cooper D., Yousem S. A. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung. Mod Pathol. 1996 May;9(5):484–490. [PubMed] [Google Scholar]
  12. Hockenbery D. M., Zutter M., Hickey W., Nahm M., Korsmeyer S. J. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):6961–6965. doi: 10.1073/pnas.88.16.6961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hsieh T. C., Xu W., Chiao J. W. Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium. Exp Cell Res. 1995 May;218(1):137–143. doi: 10.1006/excr.1995.1140. [DOI] [PubMed] [Google Scholar]
  14. Isaacs J. T., Coffey D. S. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. 1989;2:33–50. doi: 10.1002/pros.2990150506. [DOI] [PubMed] [Google Scholar]
  15. Jen P. Y., Dixon J. S. Development of peptide-containing nerves in the human fetal prostate gland. J Anat. 1995 Aug;187(Pt 1):169–179. [PMC free article] [PubMed] [Google Scholar]
  16. Krajewska M., Krajewski S., Epstein J. I., Shabaik A., Sauvageot J., Song K., Kitada S., Reed J. C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 1996 May;148(5):1567–1576. [PMC free article] [PubMed] [Google Scholar]
  17. Krajewski S., Bodrug S., Krajewska M., Shabaik A., Gascoyne R., Berean K., Reed J. C. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol. 1995 Jun;146(6):1309–1319. [PMC free article] [PubMed] [Google Scholar]
  18. Lu Q. L., Abel P., Foster C. S., Lalani E. N. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol. 1996 Feb;27(2):102–110. doi: 10.1016/s0046-8177(96)90362-7. [DOI] [PubMed] [Google Scholar]
  19. McDonnell T. J., Troncoso P., Brisbay S. M., Logothetis C., Chung L. W., Hsieh J. T., Tu S. M., Campbell M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992 Dec 15;52(24):6940–6944. [PubMed] [Google Scholar]
  20. Moll R., Franke W. W., Schiller D. L., Geiger B., Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982 Nov;31(1):11–24. doi: 10.1016/0092-8674(82)90400-7. [DOI] [PubMed] [Google Scholar]
  21. Motoyama N., Wang F., Roth K. A., Sawa H., Nakayama K., Nakayama K., Negishi I., Senju S., Zhang Q., Fujii S. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science. 1995 Mar 10;267(5203):1506–1510. doi: 10.1126/science.7878471. [DOI] [PubMed] [Google Scholar]
  22. Nagle R. B. A review of intermediate filament biology and their use in pathologic diagnosis. Mol Biol Rep. 1994 Jan;19(1):3–21. doi: 10.1007/BF00987318. [DOI] [PubMed] [Google Scholar]
  23. Nakada S. Y., di Sant'Agnese P. A., Moynes R. A., Hiipakka R. A., Liao S., Cockett A. T., Abrahamsson P. A. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res. 1993 May 1;53(9):1967–1970. [PubMed] [Google Scholar]
  24. Noordzij M. A., van Weerden W. M., de Ridder C. M., van der Kwast T. H., Schröder F. H., van Steenbrugge G. J. Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol. 1996 Sep;149(3):859–871. [PMC free article] [PubMed] [Google Scholar]
  25. Okada H., Tsubura A., Okamura A., Senzaki H., Naka Y., Komatz Y., Morii S. Keratin profiles in normal/hyperplastic prostates and prostate carcinoma. Virchows Arch A Pathol Anat Histopathol. 1992;421(2):157–161. doi: 10.1007/BF01607049. [DOI] [PubMed] [Google Scholar]
  26. Segal N. H., Cohen R. J., Haffejee Z., Savage N. BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med. 1994 Jun;118(6):616–618. [PubMed] [Google Scholar]
  27. Sjöberg H. E., Arver S., Bucht E. High concentration of immunoreactive calcitonin of prostatic origin in human semen. Acta Physiol Scand. 1980 Sep;110(1):101–102. doi: 10.1111/j.1748-1716.1980.tb06636.x. [DOI] [PubMed] [Google Scholar]
  28. Smedts F., Ramaekers F., Troyanovsky S., Pruszczynski M., Link M., Lane B., Leigh I., Schijf C., Vooijs P. Keratin expression in cervical cancer. Am J Pathol. 1992 Aug;141(2):497–511. [PMC free article] [PubMed] [Google Scholar]
  29. Thompson C. B. Apoptosis in the pathogenesis and treatment of disease. Science. 1995 Mar 10;267(5203):1456–1462. doi: 10.1126/science.7878464. [DOI] [PubMed] [Google Scholar]
  30. Ubink R., Lange W., Verhofstad A. Simultaneous immunoenzymatic staining of catecholamines, catecholamine-biosynthesizing enzymes, and bromodeoxyuridine in adrenal medullary cells of the rat. J Histochem Cytochem. 1995 Jan;43(1):39–46. doi: 10.1177/43.1.7822762. [DOI] [PubMed] [Google Scholar]
  31. Verhagen A. P., Aalders T. W., Ramaekers F. C., Debruyne F. M., Schalken J. A. Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate. 1988;13(1):25–38. doi: 10.1002/pros.2990130104. [DOI] [PubMed] [Google Scholar]
  32. Verhagen A. P., Ramaekers F. C., Aalders T. W., Schaafsma H. E., Debruyne F. M., Schalken J. A. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res. 1992 Nov 15;52(22):6182–6187. [PubMed] [Google Scholar]
  33. Verhofstad A. A. Kinetics of adrenal medullary cells. J Anat. 1993 Oct;183(Pt 2):315–326. [PMC free article] [PubMed] [Google Scholar]
  34. Weinstein M. H., Partin A. W., Veltri R. W., Epstein J. I. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol. 1996 Jul;27(7):683–687. doi: 10.1016/s0046-8177(96)90398-6. [DOI] [PubMed] [Google Scholar]
  35. Xue Y., Smedts F., Umbas R., Aalders T. W., Debruyne F. M., de la Rosette J. J., Schalken J. A. Changes in keratin expression during the development of benign prostatic hyperplasia. Eur Urol. 1997;32(3):332–338. [PubMed] [Google Scholar]
  36. de Bruïne A. P., Dinjens W. N., van der Linden E. P., Pijls M. M., Moerkerk P. T., Bosman F. T. Extracellular matrix components induce endocrine differentiation in vitro in NCI-H716 cells. Am J Pathol. 1993 Mar;142(3):773–782. [PMC free article] [PubMed] [Google Scholar]
  37. di Sant'Agnese P. A. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol. 1992 Mar;23(3):287–296. doi: 10.1016/0046-8177(92)90110-o. [DOI] [PubMed] [Google Scholar]
  38. van de Voorde W., Baldewijns M., Lauweryns J. Florid basal cell hyperplasia of the prostate. Histopathology. 1994 Apr;24(4):341–348. doi: 10.1111/j.1365-2559.1994.tb00535.x. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES